INTRODUCTION
toxicity, cancer, SRS
BRAIN METASTASES, CANCER, METASTASES
Brain metastases (BM) occur in 10%–30% of all cancer patients.Because toxicity associated with WBRT appears to be dose‐dependent, administration of SRS to a sufficient number of BM could decrease selectivity and conformality to such a degree that the dose of radiation delivered to normal brain tissue approaches that associated with WBRT, thereby negating any safety benefit.In this study, we estimate the maximum number of BM that can be treated using single and multi‐session SRS while limiting the dose of radiation delivered to normal brain tissue to that associated with WBRT. In addition, we estimate the mean dose of radiation delivered to the brain after administration of SRS to single metastases of various sizes.